Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC

Currently, the benefits of immune checkpoint inhibitor (ICI) therapy prediction via emerging biomarkers have been identified, and the association between genomic mutation signatures (GMS) and immunotherapy benefits has been widely recognized as well. However, the evidence about non-small cell lung c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zemin, Ge, You, Li, Han, Fei, Gaoqiang, Wang, Shuai, Wei, Pingmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702799/
https://www.ncbi.nlm.nih.gov/pubmed/36305643
http://dx.doi.org/10.1042/BSR20220892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702799/
https://www.ncbi.nlm.nih.gov/pubmed/36305643
http://dx.doi.org/10.1042/BSR20220892

Ejemplares similares